Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

HHS - 5237 - Secretary's Advisory Committee On Genetic Testing - Authorized by Law


Committee NameSecretary's Advisory Committee On Genetic TestingAgency NameDepartment of Health and Human Services
Fiscal Year2002Committee Number5237
Original Establishment Date6/10/1998Committee StatusTerminated
Actual Termination Date8/10/2002Committee URL
New Committee This FYNoPresidential Appointments*No
Terminated This FYYesMax Number of Members*19
Current Charter Date6/10/2002Designated Fed Officer Position Title*Executive Secretary
Date Of Renewal Charter Designated Federal Officer PrefixMs.
Projected Termination Date Designated Federal Officer First Name*Sarah
Exempt From Renewal*NoDesignated Federal Officer Middle Name
Specific Termination AuthorityDesignated Federal Officer Last Name*Carr
Establishment Authority*Authorized by LawDesignated Federal Officer Suffix
Specific Establishment Authority*42 U.S.C. 217aDesignated Federal Officer Phone*301-496-9838
Effective Date Of Authority*11/17/1962Designated Federal Officer Fax*301-496-9839
Exempt From EO 13875 Discretionary Cmte Designated Federal Officer Email*
Committee Type*Continuing
Committee Function*National Policy Issue Advisory Board


Agency Recommendation*Terminate
Legislation to Terminate Required 
Legislation Status 
How does cmte accomplish its purpose?*This committee was composed of highly qualified experts in issues related to genetic testing. They provided a breadth and balance of specialized knowledge necessary to recommend policies and procedures for the safe and effective incorporation of genetic technologies into health care; assessing the effectiveness of existing and future measures for oversight of genetic tests; and identifying research needs related to the Committee's purview.
How is membership balanced?*The committee consisted of 13 members, including the Chair, and 7 non-voting ex-officio members. Members and the Chair were selected by the Secretary, or designee, from authorities knowledgeable in the fields of genetic testing, medical genetics, genetic counseling, ethics, law, primary health care, public health, clinical laboratory management, diagnostic technology, psychology, social sciences, and other relevant disciplines. One member was a member of the Clinical Laboratory Improvement Advisory Committee, one member was a member of the Medical Devices Advisory Committee, and at least one member was specifically selected for knowledge/expertise as a consumer of health care services.
How frequent & relevant are cmte mtgs?*The committee met four times during the reporting period. They continued to address the oversight of genetic tests and remain actively involved in the development and implementation of a pre-market review process for new genetic tests as well as a program for post-market data collection and dissemination efforts. The committee developed, gathered public comment and sought expert advice on a proposed template for genetic test information for use by health professionals and a proposed classification methodology for determining level of review for genetic tests, which culminated in the preparation of a report to the Secretary on the development of a classification methodology for genetic tests. In addition, the committee made recommendations on gene patents and licensing, genetic non-discrimination legislation, and informed consent of third parties indirectly involved in genetic research. They continued to address issues relating to institutional review boards and informed consent for genetic testing in clinical and public health practice; access to genetic tests and services; health disparities as it relates to genetic testing; genetics education of heath professionals; and development, provision, and review of tests for rare genetic diseases.
Why advice can't be obtained elsewhere?*After a broad review of the functions of its advisory committee, HHS determined that the Committee's functions as set for th in its charter should be broadened. Consequently, a new committee with a mandate encompassing genetic technologies and their health and social implications was chartered on November 6, 2002. The new committee is called the Secretary's Advisory Committee on Genetics, Health, and Society.
Why close or partially close meetings?N/A
Recommendation Remarks


Outcome Improvement To Health Or Safety* Action Reorganize Priorities* 
Outcome Trust In Government Action Reallocate Resources 
Outcome Major Policy Changes Action Issued New Regulations 
Outcome Advance In Scientific Research Action Proposed Legislation 
Outcome Effective Grant Making Action Approved Grants Or Other Payments 
Outcome Improved Service Delivery Action Other 
Outcome Increased Customer Satisfaction Action Comment
Outcome Implement Laws/Reg Requirements Grants Review* 
Outcome Other Number Of Grants Reviewed 
Outcome CommentNumber Of Grants Recommended 
Cost Savings* Dollar Value Of Grants Recommended 
Cost Savings CommentGrants Review Comment
Number Of Recommendations* Access Contact Designated Fed. Officer* 
Number Of Recommendations CommentAccess Agency Website 
% of Recs Fully Implemented* Access Committee Website 
% of Recs Fully Implemented CommentAccess GSA FACA Website 
% of Recs Partially Implemented* Access Publications 
% of Recs Partially Implemented CommentAccess Other 
Agency Feedback* Access Comment
Agency Feedback Comment*Narrative Description*
Hide Section - COSTS


Payments to Non-Federal Members*$18,600.00Est Payments to Non-Fed Members Next FY*$0.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$258,705.00Estimated Payments to Federal Staff*$0.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$31,834.00Est Travel Reimb Non-Fed Members nextFY*$0.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$361,849.00Est. Other Costs Next FY*$0.00
Total Costs$670,988.00Est. Total Next FY*$0.00
Federal Staff Support (FTE)*3.00Est. Fed Staff Support Next FY*0.00
Cost RemarksEst Cost Remarks
Hide Section - Interest Areas

Interest Areas

No interest areas selected for this committee.


To View all the members, meetings and advisory reports for this committee please click here


No Documents Found



Data from Previous Years

ActionCommittee System IDCommittee NameFiscal Year
 COM-017617Secretary's Advisory Committee On Genetic Testing2001
 COM-018507Secretary's Advisory Committee On Genetic Testing2000
 COM-019766Secretary's Advisory Committee On Genetic Testing1999
 COM-020388Secretary's Advisory Committee On Genetic Testing1998